Up to 15 percent of people with MS are diagnosed with primary progressive multiple sclerosis (PPMS).

The disease is named “primary progressive” because it progresses from the onset of the first (primary) symptoms. PPMS symptoms steadily worsen over time without relapses or remissions, unlike relapsing-remitting multiple sclerosis (RRMS), which is characterized by exacerbations followed by periods of symptom-free remission.

The progression of symptoms in PPMS varies between patients. The disease is called “active” when a patient experiences occasional relapses or there is evidence of new lesions on an MRI. “Not active” or “with progression” means there is evidence that a symptom is worsening over time with or without relapse, or new lesions are shown on an MRI.

People with PPMS have fewer brain lesions and inflammation than people with RRMS. Conversely, people with PPMS usually have more spinal cord lesions than people with RRMS.

PPMS diagnosis

Accurate diagnose of PPMS requires at least three characteristics. The patient must have one year of disease progression (worsening of neurological function without remission), and two additional characteristics that could include a brain lesion that is recognized as typical of MS, two or more lesions of a similar pattern in the spinal cord, or evidence of immune system activity in the central nervous system (shown in an elevated IgG index or an oligoclonal band in the spinal fluid).

PPMS diagnosis can take a long time, especially in cases when neurologic symptoms have just begun. In fact, PPMS diagnosis can take two to three years longer than RRMS diagnosis.

Typically, PPMS is diagnosed between 40 and 60 years old, but earlier diagnosis can happen. The disease affects women and men equally.  People with PPMS usually experience more problems with walking and working, and may require assistance for everyday activities.

Treating PPMS

On March 28 2017, Ocrevus (ocrelizumab) became the first treatment approved by the U.S. Food and Drug Administration (FDA) specifically to treat PPMS. In clinical trials, Ocrevus slowed disease progression in PPMS patients.

Other treatments are still in development. There are ongoing clinical trials (such as NCT02284568NCT01776060 and NCT02913157) assessing various experimental PPMS medications.

People who experience relapses or show evidence of disease activity on an MRI are sometimes prescribed approved RRMS disease-modifying therapies that are made to reduce inflammation in the central nervous system.

There are also ways for PPMS patients to manage the disease, beyond medication. Appropriate exercise and healthy eating habits are important for people with MS. When relapse or worsening of symptoms occur, physical and occupational therapy can help minimize muscle weakness and help restore movement.

Be sure to follow the latest developments on PPMS treatments by following Multiple Sclerosis News Today’s Progressive Multiple Sclerosis Experimental Therapy Tracker.

SMA News Today is strictly a news and information website about the disease. It does not provide medical advice, diagnosis or treatment. This content is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read on this website.


Dr. Patricia Coyle at CMSC 2016 Discussing Progressive MS Treatment

RRMS Diagnosed Most Often in Younger Women and PPMS in Older Men, European Study Reports

Women with multiple sclerosis are being diagnosed at younger ages and in greater numbers than men, except for those with primary progressive disease (PPMS), where men 50 or older tend to predominate, a European review study that looked at trends over several decades reports. The study “Age‐dependent variation of female preponderance across different phenotypes of multiple […]

Ocrevus Helps Preserve Hand and Arm Function in PPMS Patients, Trial Data Show

Treating primary progressive multiple sclerosis (PPMS) patients with Ocrevus (ocrelizumab) can help to preserve strength and function in their hands and the arms, analysis of data from a Phase 3 trial found. The research, “Ocrelizumab reduces progression of upper extremity impairment in patients with primary progressive multiple sclerosis: Findings from the phase III randomized ORATORIO trial,” […]

MS News that Caught My Eye Last Week: Ocrevus in the UK, Environmental Triggers, PPMS Research

NICE Postpones Final Opinion on Adding Ocrevus to Public Health System for PPMS Patients in UK This last-minute reprieve from the agency that dictates which medications may be prescribed for patients of the U.K.’s National Health Service (NHS) is welcome news. Last summer, the National Institute for Health and Care Excellence (NICE) said the benefits […]

NICE Postpones Final Opinion on Adding Ocrevus to Public Health System for PPMS Patients in UK

A final and weighty opinion regarding whether Ocrevus (ocrelizumab) will be among treatments available at low or no cost to primary progressive multiple sclerosis (PPMS) patients in England and Wales — through the National Health Service (NHS) — has been put on hold, according to the Multiple Sclerosis Trust. The “final guidance” from  The National Institute of Health […]

#ECTRIMS2018 – Ocrevus Used Early in MS Course Key to Slowing Disability, Genentech Director Says

Treating patients with primary progressive or relapsing multiple sclerosis (MS) early with Ocrevus (ocrelizumab) is key to slowing disease progression, according to Hideki Garren, global head of Multiple Sclerosis and Neuroimmunology at Genentech. In an interview with Multiple Sclerosis News Today at the recent 34th congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS), Garren, who is […]

#ECTRIMS2018 – Finding Best Treatment for ‘Right Patient’ and Progressive MS Among Work of Interest, Cleveland Clinic Doctors Say

Tailored, highly effective therapies early in the disease’s course may be a way forward in multiple sclerosis (MS) treatment, according to Cleveland Clinic neurologist Robert Bermel. Another neurologist with the Cleveland Clinic, Robert Fox, talked about potential and upcoming progressive MS treatments.  In interviews with Multiple Sclerosis News Today at the recent 34th congress of the European Committee for […]

#ECTRIMS2018 – Blood Level of Neurofilament Light Chain May Predict Brain Atrophy in Progressive MS, Study Suggests

Measuring the blood level of neurofilament light chain (NfL) may predict brain shrinkage in primary progressive (PPMS) and secondary progressive multiple sclerosis (SPMS), according to a new study. The findings also show that NfL levels are associated with brain lesion load in these patients. The research, “Neurofilament light levels in the blood of patients with […]

PPMS Suddenly and Spontaneously Surges My Symptoms

When I was diagnosed in 2010 with primary progressive multiple sclerosis (PPMS), I didn’t know what to expect. It quickly became apparent that my doctors didn’t know, either. I’m sure they could have given me some scenarios of what my future might be like. But just like the disease itself, the course of progression is […]

MS News that Caught My Eye Last Week: Treating MS with a Statin, Ocrevus, Remyelination

Phase 3 Trial in the UK Soon to Test Statin, Simvastatin, in Slowing SPMS Progression I’ve taken a statin medication for years to keep my cholesterol in check. Now, a study is getting underway to see if one statin pill can also be used to treat MS. It’s particularly encouraging that this med is being […]